This article and associated images are based on a poster originally authored by Amy Turner, Poppy Nathan, Yanan Lu, Deepa Shankar, Danielle Callahan, Lion Lian and Jason Li and presented at ELRIG Drug Discovery 2025 in affiliation with Proteintech Group.
This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment.
Introduction
The design and interpretation of both experimental and therapeutic studies critically depend on the availability of high-quality, well-defined reagents.
Antibodies and recombinant proteins remain central to fundamental research and therapeutic development, yet conventional reagent production methods often lack the epitope specificity, consistency, and scalability required to drive next-generation experimental and therapeutic innovation.
Proteintech has evolved into a leading recombinant reagent provider, leveraging the proprietary Antigen-Specific B-Cell Cloning and Engineering (ABCE™) recombinant antibody platform, Chromotek® NANOBODY®-based reagents, and the largest portfolio of cGMP-grade, human-cell expressed cytokines and growth factors.
By offering in-house manufactured recombinant reagents, Proteintech ensures lot-to-lot consistency, scalability, and the traceability necessary to accelerate discovery and translation.
Together with a comprehensive recombinant portfolio, AI-powered search tools have been built to optimize reagent selection and experimental design. Firstly, comprehensive 3D epitope mapping using a combination of structural, computational, and fragment-based approaches has been performed to generate open-access 3D maps of over 2500 targets and their associated antibody binding sites.
Secondly, Able, a first-of-its-kind AI-powered search tool, has been released that integrates epitope-information, published literature, and application-specific metadata to guide researchers toward the most appropriate reagents and protocols for their experimental or therapeutic objectives.
The combination of epitope-defined recombinant reagents and intelligent search platforms represents a new standard for enhancing both experimental robustness and the rational design of therapeutic strategies. This poster highlights the benefits of recombinant reagents in research and the open-access resources available to researchers to find them.
Ruo and cGMP grade recombinant reagents
Recombinant antibodies and matched antibody pairs
Proteintech’s proprietary Antigen-Specific B-cell Cloning & Engineering (ABCE™) platform harnesses 20+ years of poly- and monoclonal antibody manufacturing experience, and produces recombinant antibodies three times faster than competitors (six weeks vs six months).
This streamlined workflow will generate sequence-defined antibodies for over 3000 targets every year, with the projection to cover the entirety of the human proteome by 2030. The ABCE™ platform shows:
- High-throughput target coverage and production
- Rigorously screened with a three-tier validation process
- Excellent specificity with high and defined affinity
- Unparalleled lot-to-lot consistency
- High purity due to two-step purification
- Scalable custom options with secure supply.
Due to the sequence definition of these recombinant reagents, straightforward antibody engineering has ensued, with Proteintech now offering alternative antibody formats (Figure 1). Figure 1A represents the FcZero-rAb, the backbone of which has been mutated to ablate Fc receptor binding, eliminating the need for blocking in flow cytometry pipelines, and offering advantages in therapeutic design.
FcZero-rAb also features AccuBright™ site-specific, stoichiometric conjugation, allowing customizability for ADCs and other payloads. Figures 1B-1G show alternate binding scaffolds that present advantages such as smaller size for enhanced tissue penetration, reduced risk of off-target immune activation, and ease of modulation for bispecifics or CARs.
Together with a growing recombinant antibody offering, Proteintech holds the largest portfolio of matched antibody pairs covering over 3600 human targets, with multiple pairing combinations available, including those for IL-6 (Figure 2).
The pairs are validated using Proteintech's proprietary in-house multiplex bead array technology and sandwich ELISA platforms, and are ready for a wide variety of multiplex platforms, including:
- ELISA
- FRET
- Multiplex IF/ FC
- Lateral flow assays
- Proximity ligase assays
- Bead-based arrays.
Figure 1. Alternative antibody formats available from Proteintech. Image Credit: Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
Figure 2. Matched Antibody Pairs. A) Schematic representation of capture–detection antibody configuration. B) Sandwich ELISA standard curve of Human IL6 Recombinant Matched Antibody Pair (MP00687-4). Image Credit: Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
HumanKine® cytokines and growth factors
Proteintech has the largest portfolio of in-house manufactured, GMP-grade cytokines and growth factors, with robust scalability from preclinical to clinical and commercial quantities.
The recombinant proteins are human cell (HEK293) expressed, maintaining native folding and post-translational modifications, meaning higher bioactivity compared to E. coli-derived counterparts (Figure 3). Furthermore, they are animal-component-free, endotoxin-free, xeno-free, tag-free, and carrier-free.
- Authentic human proteins
- Native human conformation and post-translational modifications
- High bioactivity and stability
- Seamless transition from research to cGMP.
Figure 3. HumanKine® proteins show higher bioactivity than competitor products. A) IL-2 induction of CTLL-2 cells (mouse cytotoxic T cells) by HumanKine IL-2 vs leading competitor. B) HumanKine IL-2 demonstrates greater levels of γδ T cell expansion and proliferation compared to competitor product. C) HumanKine BDNF demonstrated significantly better SH-SY5Y neuronal cell differentiation in comparison to competitor product. D) HumanKine BDNF demonstrated equivalent fold induction and a greater than 6-fold increase in potency compared to leading competitors. Image Credit: (A and B: Dr. Leonardo Castrillo and Dr. Alessandro Poggi, IRCCS Ospedale Policlinico San Martino, unit of Molecular Oncology and Angiogenesis, Genoa, Italy); Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
Chromotek® NANOBODY® - based reagents
Complementing Proteintech’s growing recombinant offering is the Chromotek Nanobody-based reagent portfolio. Figure 4 shows example reagents.
Due to their size (12-15 kDa) and single-chain characteristic, they provide a higher level of performance than conventional IgG antibodies in applications such as immunoprecipitation, immunofluorescence, live-cell imaging, biosensor assays, and protein purification.
Figure 4. Schematic examples of Chromotek Nanobody-based reagents. A) Fluorescently conjugated primary VHH for immunofluorescence B) VHH-conjugated beads for immunoprecipitation C) Fluorescent nanoprobes (Chromobodies®) for real-time and live cell imaging. Image Credit: Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
Industry leading AI-powered search tools for optimized reagent selection
Proteintech's 3D Epitope Viewer is an advanced validation initiative that provides interactive 3D maps of antibody binding sites (epitopes) on over 2500 target proteins. This open-access, innovative tool allows more accurate predictions of cross-reactivity, epitope masking, domain accessibility, and more (Figure 5A).
Additionally, the immunogen selector module allows precise targeting of domains/ terminals of interest, narrowing search results to available antibodies directly targeting these regions (Figure 5B). Finally, Proteintech has built Able, an AI-powered search tool capable of assisting researchers in reagent selection, experimental design, literature searches, and much more.
Open access 3D Epitope Viewer
Figure 5. Proteintech’s open access tools to improve. A) 3D epitope viewer of two distinct beta actin epitopes with associated antibody options. B) Immunogen selector module. Image Credit: Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
Able AI-powered search tool
Image Credit: Image courtesy of Amy Turner et al., in partnership with ELRIG (UK) Ltd.
- Tailored product recommendations for research areas and applications, e.g., “Find markers for subcellular organelles”
- Builds on the 3D Epitope Viewer to provide deeper experimental insights in combination with internal and external validation data, citations, and other metadata sources
- Understands and responds in multiple languages to democratize global research.
Conclusion
Proteintech’s comprehensive recombinant reagent portfolio, including recombinant antibodies, Humankine cytokines and growth factors, and Chromotek Nanobody-based tools, provides researchers with consistent, scalable, and highly reproducible solutions for drug discovery. Coupled with innovative digital resources such as the 3D Epitope Viewer and the Able AI-powered search tool, Proteintech continues to empower scientists to accelerate discovery, streamline workflows, and advance translational research.
About Proteintech Group, Inc
Proteintech are a global biotech company and a renowned center of excellence for the manufacture and supply of quality antibodies, ELISA kits and proteins to the life science research community.
About ELRIG (UK) Ltd.
The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organization is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.
Comprised of a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organizations, on an open access basis, as all our events are free-of-charge to attend!
Our values
Our values are to always ensure the highest quality of content and that content will be made readily accessible to all, and that we will always be an inclusive organization, serving a diverse scientific network. In addition, ELRIG will always be a volunteer led organization, run by and for the life sciences community, on a not-for-profit basis.
Our purpose
ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate, on an open access basis. We achieve this through the provision of world class conferences, networking events, webinars and digital content.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
Last Updated: Nov 12, 2025